Table 1.
Baseline characteristics of eligible men with HIV by NRTI combination group, Veterans Aging Cohort Study, February 2020 – October 2021
| TAF/FTC (N=12,707) |
TDF/FTC (N=933) |
ABC/3TC (N=3,805) |
Other (N=3,049) |
|
|---|---|---|---|---|
| Mean age (SD), years | 58.0 (12.1) | 58.7 (11.8) | 58.9 (12.5) | 61.2 (11.7) |
| Age, years | ||||
| 18–39 | 1393 (11.0%) | 84 (9.0%) | 408 (10.7%) | 224 (7.3%) |
| 40–49 | 1446 (11.4%) | 115 (12.3%) | 405 (10.6%) | 233 (7.6%) |
| 50–59 | 3695 (29.1%) | 277 (29.7%) | 992 (26.1%) | 774 (25.4%) |
| 60–69 | 4131 (32.5%) | 302 (32.4%) | 1261 (33.1%) | 1112 (36.5%) |
| 70+ | 2042 (16.1%) | 155 (16.6%) | 739 (19.4%) | 706 (23.2%) |
| Race/Ethnicity | ||||
| Non-Hispanic White | 4696 (37.0%) | 361 (38.7%) | 1292 (34.0%) | 1059 (34.7%) |
| Non-Hispanic Black | 5265 (41.4%) | 438 (46.9%) | 1873 (49.2%) | 1492 (48.9%) |
| Hispanic | 1158 (9.1%) | 75 (8.0%) | 271 (7.1%) | 227 (7.4%) |
| Other/unknown | 1588 (12.5%) | 59 (6.3%) | 369 (9.7%) | 271 (8.9%) |
| Smoking status | ||||
| Never | 4449 (35.0%) | 285 (30.5%) | 1297 (34.1%) | 985 (32.3%) |
| Current | 5711 (44.9%) | 454 (48.7%) | 1732 (45.5%) | 1454 (47.7%) |
| Former | 2547 (20.0%) | 194 (20.8%) | 776 (20.4%) | 610 (20.0%) |
| Mean CD4 cell count (SD), cells/μL | 676 (306) | 699 (311) | 699 (311) | 623 (309) |
| Detectable HIV viral load (≥50 copies/mL) | 806 (6.3%) | 52 (5.6%) | 215 (5.7%) | 198 (6.5%) |
| Detectable max viral load over the past 12 months (≥50 copies/mL) | 1834 (14.4%) | 105 (11.3%) | 451 (11.9%) | 458 (15.0%) |
| Mean BMI (SD), kg/m2 | 28.2 (5.41) | 27.5 (5.54) | 27.7 (5.34) | 27.1 (5.41) |
| Mean systolic blood pressure (SD), mmHg | 129 (11.6) | 129 (12.4) | 130 (12.2) | 130 (12.7) |
| Mean diastolic blood pressure (SD), mmHg | 77.9 (7.28) | 78.4 (7.44) | 78.2 (7.22) | 77.0 (7.80) |
| Mean eGFR within one year before baseline | ||||
| eGFR > 90 mL/min | 1821 (14.3%) | 202 (21.7%) | 368 (9.7%) | 396 (13.0%) |
| eGFR = 60–90 mL/min | 6381 (50.2%) | 504 (54.0%) | 1664 (43.7%) | 1200 (39.4%) |
| eGFR < 60 mL/min | 2292 (18.0%) | 86 (9.2%) | 1081 (28.4%) | 876 (28.7%) |
| Missing | 2213 (17.4%) | 141 (15.1%) | 692 (18.2%) | 577 (18.9%) |
| Baseline month | ||||
| Feb 2020 | 10732 (84.5%) | 811 (86.9%) | 3263 (85.8%) | 2515 (82.5%) |
| After Feb 2020 | 1975 (15.5%) | 122 (13.1%) | 542 (14.2%) | 534 (17.5%) |
| Hospitalization in previous month | 31 (0.2%) | 1 (0.1%) | 13 (0.3%) | 13 (0.4%) |
| Comorbidities | ||||
| Osteoporosis | 321 (2.5%) | 10 (1.1%) | 113 (3.0%) | 96 (3.1%) |
| Myocardial infarction | 38 (0.3%) | 2 (0.2%) | 12 (0.3%) | 18 (0.6%) |
| Heart Failure | 274 (2.2%) | 11 (1.2%) | 78 (2.1%) | 126 (4.1%) |
| Hypertension | 3962 (31.2%) | 277 (29.7%) | 1300 (34.2%) | 1061 (34.8%) |
| Ischemic stroke | 214 (1.7%) | 10 (1.1%) | 83 (2.2%) | 80 (2.6%) |
| Unstable angina | 30 (0.2%) | 0 (0%) | 6 (0.2%) | 21 (0.7%) |
| Chronic kidney disease | 1037 (8.2%) | 42 (4.5%) | 546 (14.3%) | 468 (15.3%) |
| Cancer | 648 (5.1%) | 55 (5.9%) | 215 (5.7%) | 192 (6.3%) |
| Metastatic cancer | 72 (0.6%) | 5 (0.5%) | 19 (0.5%) | 18 (0.6%) |
| Hepatitis B | 180 (1.4%) | 8 (0.9%) | 19 (0.5%) | 43 (1.4%) |
| Hepatitis C | 243 (1.9%) | 14 (1.5%) | 69 (1.8%) | 87 (2.9%) |
| Mild liver disease | 1265 (10.0%) | 87 (9.3%) | 386 (10.1%) | 343 (11.2%) |
| Severe liver disease | 55 (0.4%) | 4 (0.4%) | 20 (0.5%) | 22 (0.7%) |
| Asthma | 347 (2.7%) | 25 (2.7%) | 102 (2.7%) | 90 (3.0%) |
| Chronic obstructive pulmonary disease | 804 (6.3%) | 67 (7.2%) | 258 (6.8%) | 271 (8.9%) |
| Pneumonia | 253 (2.0%) | 13 (1.4%) | 89 (2.3%) | 112 (3.7%) |
| Bronchiectasis/ Pulmonary fibrosis/ Pulmonary hypertension | 145 (1.1%) | 5 (0.5%) | 37 (1.0%) | 42 (1.4%) |
| Alcohol use disorder | 834 (6.6%) | 43 (4.6%) | 253 (6.6%) | 202 (6.6%) |
| Opioid use disorder | 173 (1.4%) | 12 (1.3%) | 74 (1.9%) | 69 (2.3%) |
| Diabetes | 1444 (11.4%) | 75 (8.0%) | 429 (11.3%) | 368 (12.1%) |
| Dementia | 112 (0.9%) | 11 (1.2%) | 38 (1.0%) | 56 (1.8%) |
| Rheumatoid arthritis | 32 (0.3%) | 5 (0.5%) | 13 (0.3%) | 13 (0.4%) |
Abbreviations: 3TC – lamivudine; ABC – abacavir; FTC – emtricitabine; NRTI – nucleoside reverse transcriptase inhibitor; TDF – tenofovir disoproxil fumarate; TAF – tenofovir alafenamide; SD – standard deviation; BMI – body mass index; eGFR – estimated glomerular filtration rate